Silver Book Fact

Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.

Papaioannou A, Watts N, Kendler D, et al. Diagnosis and Management of Vertebral Fractures in Elderly Adults. Am J Med. 2002; 113(3): 220-8. http://www.amjmed.com/article/S0002-9343(02)01190-7/abstract

Reference

Title
Diagnosis and Management of Vertebral Fractures in Elderly Adults
Publication
Am J Med
Publication Date
2002
Authors
Papaioannou A, Watts N, Kendler D, et al
Volume & Issue
Volume 113, Issue 3
Pages
220-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.